Research & Development
Patients with critical illness deserve individualized care. Our strategy is to bring precision medicine – the same methodology that transformed cancer care – to the treatment of immune-driven conditions.
Data-Driven Discovery
Our R&D strategy begins with data. Prenosis has built one of the largest acute illness biobanks in existence, pairing biological signatures with clinical outcomes across thousands of patients. This foundation – powered by our proprietary precision medicine platform – enables our data scientists to identify which combinations of biomarkers can predict how a patient will respond to treatment.
Clinical Trials for Acute Care
Built for Critical Conditions, Proven with Academic Research
Because critical conditions move fast, our tools are designed to be deployed immediately at the point of decision. In partnership with leading academic research centers and networks, we’re advancing this work through clinical trials focused on conditions where the stakes are highest. These studies will help us understand which patients are at risk, and which interventions are appropriate for them.
Research is the Backbone of Our Mission
Disrupt with Evidence
Before we brought our first product to market, we spent a decade building the evidence behind it, gathering biological data, collaborating with leading health systems, and rigorously testing our models before achieving external validation. That discipline drives everything we do today. No shortcuts, no assumptions. Only conclusions backed by data.
Peer-Reviewed Evidence
Published in leading scientific journals, our data scientists and clinical researchers contribute to a growing body of peer-reviewed evidence on the biology of acute illness, with more research underway.
Research with Leading Academic Sites
Our precision medicine platform enables an entirely new approach to clinical trials, focused on rapidly identifying the right patients for targeted therapies.
Sepsis and Beyond
We began with sepsis. Our Immunix platform will be the basis to extend the same rigorous, data-driven approach to a broader set of critical conditions, such as ARDS, pneumonia, and acute heart failure.